FCM
KALV

Farallon Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Farallon Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200,000
Closed -$4.42M – 99
2018
Q3 		$4.42M Buy
+200,000
New +$2.7M 0.03% 91

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Farallon Capital Management's KALV Position: Q4 2018 in Review

Farallon Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q4 2018, closing a stake of 200,000 shares — an estimated $4.42M sold.

Farallon Capital Management first reported a position in KALV in Q3 2018 and held it in 1 quarter. The position peaked at $4.42M in Q3 2018. 57 funds tracked by Wall St. Rank hold KALV as of Q4 2018.

  • Farallon Capital Management reported no remaining KalVista Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Farallon Capital Management sold 200,000 KalVista Pharmaceuticals shares in Q4 2018, an estimated $4.42M.
  • Farallon Capital Management first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Farallon Capital Management's KalVista Pharmaceuticals position peaked at $4.42M in Q3 2018.
  • 57 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2018.

Based on Farallon Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.